BREAKING: Ionis Pharmaceuticals plunged 29% to $28.15 — its worst single-day drop since 2016 — after halving its full-year sales outlook for Tryngolza to about $50M, down from $100M-$110M, on a slower-than-expected launch. Tryngolza brought in just $9M in Q3, well below estimates of $25M+. The quarter itself beat: Q3 revenue $243M vs $178.2M expected, a loss of $0.66/share vs $1.01 expected, and total 2026 revenue guidance held at $875M-$900M.
#Ionis #IONS #Biotech #Stocks #Earnings #StockMarket
#Ionis #IONS #Biotech #Stocks #Earnings #StockMarket
183 Views